DI FEDERICO, ALESSANDRO

DI FEDERICO, ALESSANDRO  

DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE  

Assegnisti  

Mostra records
Risultati 1 - 20 di 49 (tempo di esecuzione: 0.042 secondi).
Titolo Autore(i) Anno Periodico Editore Tipo File
Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanoma Di Federico A.; Filippini D.M.; Sperandi F.; Ardizzoni A.; Melotti B. 2021-01-01 EUROPEAN JOURNAL OF CANCER - 1.01 Articolo in rivista -
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease Metro G.; De Giglio A.; Ricciuti B.; Siringo M.; Marinelli D.; Gelibter A.; Pecci F.; Berardi R.;... Cantini L.; Di Federico A.; Andrini E.; Mosca M.; Lamberti G.; Brambilla M.; Mountzios G. 2022-01-01 DRUGS IN CONTEXT - 1.01 Articolo in rivista -
Advanced non-small-cell lung cancer: how to manage non-oncogene disease De Giglio A.; Di Federico A.; Deiana C.; Ricciuti B.; Brambilla M.; Metro G. 2022-01-01 DRUGS IN CONTEXT - 1.01 Articolo in rivista dic.2022-2-4.pdf
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G. 2022-01-01 EXPERT OPINION ON INVESTIGATIONAL DRUGS - 1.01 Articolo in rivista -
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A. 2020-01-01 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY - 1.01 Articolo in rivista -
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients De Giglio A.; Deiana C.; Di Federico A. 2023-01-01 JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY - 1.01 Articolo in rivista -
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review Nigro M.C.; Marchese P.V.; Deiana C.; Casadio C.; Galvani L.; Di Federico A.; De Giglio A. 2023-01-01 LUNG CANCER: TARGETS AND THERAPY - 1.01 Articolo in rivista -
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma Scalera S.; Ricciuti B.; Mazzotta M.; Calonaci N.; Alessi J.V.; Cipriani L.; Bon G.; Messina B.; ...Lamberti G.; Di Federico A.; Pecci F.; Milite S.; Krasniqi E.; Barba M.; Vici P.; Vecchione A.; De Nicola F.; Ciuffreda L.; Goeman F.; Fanciulli M.; Buglioni S.; Pescarmona E.; Sharma B.; Felt K.D.; Lindsay J.; Rodig S.J.; De Maria R.; Caravagna G.; Cappuzzo F.; Ciliberto G.; Awad M.M.; Maugeri-Sacca M. 2023-01-01 ANNALS OF ONCOLOGY - 1.01 Articolo in rivista -
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppion...i E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A. 2020-01-01 LUNG CANCER - 1.01 Articolo in rivista -
Critical diagnostic delay associated with unusual presentation of hepatocellular carcinoma (Hcc) with orbital metastases: A case report Filippini D.M.; Di Federico A.; Lenzi B.; Nobili E.; Brocchi S.; Malvi D.; Brandi G. 2021-01-01 ANNALS OF PALLIATIVE MEDICINE - 1.01 Articolo in rivista Critical diagnostic delay.pdf
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, An...drea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi 2022-01-01 FUTURE ONCOLOGY - 1.01 Articolo in rivista -
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib Di Federico A.; De Giglio A.; Sperandi F.; Melotti B.; Ardizzoni A.; Gelsomino F. 2024-01-01 ANTI-CANCER DRUGS - 1.01 Articolo in rivista -
Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer De Giglio A.; Di Federico A.; Metro G. 2022-01-01 TRANSLATIONAL LUNG CANCER RESEARCH - 1.01 Articolo in rivista -
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue Rizzo A.; Ricci A.D.; Frega G.; Di Federico A.; Brandi G. 2021-01-01 EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY - 1.01 Articolo in rivista -
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) Fabbri L.; Di Federico A.; Astore M.; Marchiori V.; Rejtano A.; Seminerio R.; Gelsomino F.; De Gi...glio A. 2024-01-01 DIAGNOSTICS - 1.01 Articolo in rivista -
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; De Biase, Dario; Giunchi, Franc...esca; Palladini, Arianna; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea 2022-01-01 CANCERS - 1.01 Articolo in rivista cancers-14-03472-v2.pdfcancers-14-03472-s001.zip
Hacking pancreatic cancer: Present and future of personalized medicine Di Federico A.; Tateo V.; Parisi C.; Formica F.; Carloni R.; Frega G.; Rizzo A.; Ricci D.; Di Mar...co M.; Palloni A.; Brandi G. 2021-01-01 PHARMACEUTICALS - 1.01 Articolo in rivista Hacking Pancreatic.pdf
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible? Di Federico A.; Nuvola G.; Sisi M.; Lenzi B.; Nobili E.; Campana D. 2020-01-01 ANTI-CANCER DRUGS - 1.01 Articolo in rivista -
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies Andrini E.; Di Federico A.; Sisi M.; Rosellini M.; Palladini A.; Lamberti G.; De Giglio A.; Gelso...mino F. 2022-01-01 IMMUNOTHERAPY - 1.01 Articolo in rivista -
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects Rizzo A.; Ricci A.D.; Lanotte L.; Lombardi L.; Di Federico A.; Brandi G.; Gadaleta-Caldarola G. 2021-01-01 EXPERT OPINION ON INVESTIGATIONAL DRUGS - 1.01 Articolo in rivista -